FDA: 2×2×4 design; RSABE + ABE + σwT/σwR [Design Issues]

posted by Pharma_88 – India, 2020-03-13 10:14 (1356 d 00:10 ago) – Posting: # 21262
Views: 3,500

❝ All of the product-specific guidances contain a section ‘Explanation’. See also Yu et al.


OK

❝ ❝ Further, can we perform crossover studies for NTI by taking extra safety measurement in to the study?


❝ You can. Whether that is necessary in healthy volunteers depends on the drug.


Yes.

❝ ❝ Further, what is the BE limit for such drugs?


❝ It depends on \(\small{s_{wR}}\) observed in the study, i.e., reference-scaling is applied. Furthermore – irrespective of passing the scaled limits – the study has to pass 80.00–125.00% as well and the upper confidence limit of \(\small{\sigma_{wT}/\sigma_{wR}}\) has to be ≤2.5.


its common for all NTI or its varies from drug to drug?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,811 posts in 4,783 threads, 1,642 registered users;
23 visitors (0 registered, 23 guests [including 9 identified bots]).
Forum time: 10:25 CET (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5